🧾 What This Document Is

This is a proxy statement (DEF 14A), a formal document public companies must send to shareholders before an annual meeting. Think of it as the agenda and information packet for that meeting.

👉 Why it matters: It tells you what shareholders will vote on, who is on the board, how much the top bosses get paid, and the company's governance rules. It’s your window into how the company is run and where it’s headed.

Meeting Details: The 2026 Annual Meeting will be held virtually on May 20, 2026, at 3:00 p.m. Pacific Time at www.virtualshareholdermeeting.com/TNDM2026.

🏢 What The Company Does

In simple terms, Tandem Diabetes Care makes advanced insulin pumps and related technology for people with diabetes.

👉 The Business: They design, develop, and commercialize products like the t:slim X2 insulin pump with Control-IQ technology and the newer Tandem Mobi system. Their goal is to provide a "revolutionary experience" through connected devices, apps, and data services. They operate globally, with sales growing internationally.

🗳️ The Shareholder Vote: 7 Key Proposals

Here’s what shareholders are being asked to approve on May 20:

Elect 9 Directors to serve one-year terms.
"Say-on-Pay" Vote: A non-binding vote on the compensation of the top executives.
Approve More Stock for Employee Awards: Increase the number of shares available in the 2023 Long-Term Incentive Plan.
Allow Removal of Directors "Without Cause": A governance update to align with Delaware law.
Limit Officer Liability: Another legal update to limit the financial liability of officers, as permitted by law.
Ratify the Auditor: Approve Ernst & Young LLP as the independent accounting firm for 2026.
Other Business: Any other matters that may come up.

👥 Meet the Board & Leadership

The company proposes re-electing all nine current directors. Here’s a snapshot of the board’s expertise (ages as of the proxy):

John Sheridan (Age 70): CEO since 2019. The insider.
Rebecca Robertson: Board Chair since 2023. Leads independent directors.
Sandra Beaver (Age 48, New in 2025): Former CFO, brings deep financial expertise.
Myoungil Cha (Age 49): Expert in health tech and strategy (ex-Apple, Verily).
Peyton Howell (Age 59): CEO of Parexel, expert in healthcare services/reimbursement.
Joao Malagueira (Age 60): Global medtech leader (ex-J&J, Hologic).
Kathleen McGroddy-Goetz, Ph.D. (Age 62): AI & digital health veteran (ex-IBM Watson Health).
Rajwant Sodhi (Age 52): Digital health & software expert (ex-ResMed).
Christopher Twomey (Age 66): Long-serving director and financial expert.

👉 Why it matters: The board mixes deep diabetes industry knowledge with expertise in finance, global markets, digital health, and AI—critical for a growing medtech company.

💰 Executive Compensation: The Pay-for-Performance Story

The "Say-on-Pay" proposal asks if you approve of how the top 5 executives (NEOs) were paid in 2025.

2025 Performance Highlights Used to Justify Pay:

Surpassed $1 billion in worldwide sales.
Shipped over 126,000 pumps.
Improved gross margin to 54% (record 58% in Q4).
Achieved first positive operating margin (3%) since 2021 in Q4.

How Executive Pay is Structured (The Philosophy):

Goal: Attract/retain talent in a competitive field, align with shareholders.
Method: A "pay-for-performance" model. A significant portion of pay is at-risk—it depends on hitting company goals.
Components:
- Base Salary: Fixed cash.
- Short-Term Incentive (Bonus): Cash bonus based on hitting annual financial, product, and customer goals.
- Long-Term Incentive (Equity): Stock awards that vest over time. For 2025, a portion (50% for the CEO) was tied to 3-year performance, including a metric for Relative Total Shareholder Return (TSR) vs. peers.

2024 Say-on-Pay Vote Result: 97.14% approval. The committee views this as strong support.

2025 Compensation Changes (Responsive to Feedback):

Reduced the target for total executive pay from the 60th to the 50th percentile of their peer group.
Increased the weight of the TSR performance metric to 50% for CEO and NEO equity awards.

⚖️ Governance & Ownership

Board Structure: The roles of Chair (Rebecca Robertson) and CEO (John Sheridan) are separate, which is seen as good governance. The Chair leads the independent directors.

Major Shareholders (5%+ Owners):

BlackRock, Inc.: 14.8%
The Vanguard Group: 10.3%
Sessa Capital: 6.5%

Related Party Note: CEO John Sheridan and CFO Leigh Vosseller share a primary residence. The board was aware of this before Sheridan's 2019 promotion and has implemented "additional internal controls" around their compensation.

🔮 What's Next: 2026 Priorities

The company signals it will focus on:

Leveraging Pharmacy Access: Driving more customers through pharmacy benefits, which is better for patients and more profitable for Tandem.
International Expansion: Starting direct commercial operations in the UK, Switzerland, and Austria.
Continued Innovation: Rolling out new tech like Android control for Tandem Mobi and expanding the Tandem Source cloud infrastructure.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Surpassed $1B sales milestone, showing scale.
Clear product innovation pipeline and leadership in automated insulin delivery.
Improving financial metrics (margins, cash flow).
A board with highly relevant, diverse expertise.

⚠️ Risks & Challenges:

Intense Competition: From other major medtech and diabetes tech companies.
Execution Risk: Success depends on executing global expansion, commercial modernization, and pharmacy strategy.
Regulatory & Reimbursement: A highly regulated industry where payment policies (like pharmacy benefits) can change.
Macroeconomic Conditions: Impacts on healthcare spending and supply chains.

🧠 The Analogy

Running Tandem is like captaining a high-tech sailboat that just crossed the $1 billion ocean milestone. The crew (executives) is being rewarded for hitting speed and navigation targets. The owners (shareholders) are now being asked to 1) re-elect the experienced navigation officers (directors), 2) approve the crew's bonus plan, and 3) give the captain and crew more stock in the boat to keep them sailing together for the long haul. The new course set for 2026 involves charting direct routes in new international waters and using a promising new payment channel (pharmacy) as a faster wind.

🧩 Final Takeaway

This proxy season, Tandem Diabetes Care is asking shareholders to endorse its leadership team and pay-for-performance philosophy after a year of crossing the $1 billion sales mark. The key votes affirm the board's direction, the executive compensation plan tied to growth and shareholder returns, and governance updates, as the company navigates its next phase of global expansion and business model evolution.

TNDM Shareholders Vote on Executive Pay After $1 Billion Sales